Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable anti-tumor effects. However, a small molecule dual blockade of CD47/SIRPα a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Biomolecules
Huvudupphovsmän: Zhou, Xiuman, Jiao, Ling, Qian, Yuzhen, Dong, Qingyu, Sun, Yixuan, Zheng, Wei V., Zhao, Wenshan, Zhai, Wenjie, Qiu, Lu, Wu, Yahong, Wang, Hongfei, Gao, Yanfeng, Chen, Junhui
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2021
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8150775/
https://ncbi.nlm.nih.gov/pubmed/34068552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom11050706
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk